Thalamic metabolism and symptom onset in preclinical Huntington's disease

Brain

Volumn 130, Issue 11, 2007, Pages 2858-2867

  Feigin, A ^a,b   Tang, C ^a,b   Ma, Y ^a,b   Mattis, P ^a,c   Zgaljardic, D ^d   Guttman, M ^e   Paulsen, J S ^f   Dhawan, V ^a,b   Eidelberg, D ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c Transitional Learning Centre ^*  (United States)

^d Transitional Learning Center   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

Brain metabolism; Positron emission tomography (PET); Preclinical Huntington's disease (p HD)

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; RACLOPRIDE C 11;

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN NERVE CELL; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COVARIANCE; DISEASE COURSE; FOLLOW UP; GLUCOSE METABOLISM; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; STATISTICAL ANALYSIS; STRIATE CORTEX; THALAMUS;

EID: 35648963039     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm217     Document Type: Article

References (67)

1. Anderson KE. Huntington's disease and related disorders. Psychiatr Clin North Am 2005; 28: 275-90.
2. Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998; 43: 253-5.
3. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996; 119: 2085-95.
4. Army Individual Test Battery. Manual of Directions and Scoring. Washington, DC: War Department, Adjutant General's Office; 1944.
5. Asanuma K, Ma Y, Okulski J, Dhawan V, Chaly T, Carbon M, et al. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 2005; 64: 347-9.
6. Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997; 42: 215-21.
7. Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996; 53: 1293-6.
8. Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000; 15: 552-60.
9. Beck A. Beck Depression Inventory: Manual. San Antonio, TX: Psychological Corporation; 1987.
10. Biglan KM, Investigators P. Baseline characteristics of the prospective Huntington at risk observational study cohort. Ann Neurol 2004; 56: S24.
11. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: part 1-Correlation within subjects. Br Med J 1995; 310: 446.
12. Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005; 95: 1521-40.
13. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997; 41: 646-53.
14. Cha JH, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci 1999; 354: 981-9.
15. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994; 18: 192-205.
16. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002; 296: 2238-43.
17. Efron B, Tibshirani R. An introduction to the bootstrap. New York: CRC Press, LLC; 1994.
18. Eidelberg D, Moeller JR, Kazumata K, Antonini A, Sterio D, Dhawan V, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997; 120: 1315-24.
19. Feigin A. Evidence from biomarkers and surrogate endpoints. Neuro Rx 2004; 1: 323-30.
20. Feigin A, Ghilardi MF, Huang C, Ma Y, Carbon M, Guttman M, et al. Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol 2006; 59: 53-9.
21. Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, et al. Functional decline in Huntington's disease. Mov Disord 1995; 10: 211-4.
22. Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 2001; 42: 1591-5.
23. Feigin A, Zgaljardic D. Recent advances in Huntington's disease: implications for experimental therapeutics. Curr Opin Neurol 2002; 15: 483-9.
24. Goldon C. Stroop Color and Word Test. Chicago: Stoelting Company; 1978.
25. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996; 39: 385-9.
26. Heinsen H, Rub U, Bauer M, Ulmar G, Bethke B, Schuler M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol 1999; 97: 613-22.
27. Heinsen H, Rub U, Gangnus D, Jungkunz G, Bauer M, Ulmar G, et al. Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta Neuropathol 1996; 91: 161-8.
28. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-42.
29. Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, et al. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem 2005; 95: 553-62.
30. Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 2005; 15: 846-53.
31. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 1998; 39: 1521-30.
32. Kieburtz K, MacDonald M, Shih C, Feigin A, Steinberg K, Bordwell K, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 1994; 31: 872-4.
33. Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 2005; 76: 650-5.
34. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997; 41: 160-5.
35. Laitinen LV, Liliequist B, Fagerlund M, Eriksson AT. An adapter for computed tomography-guided stereotaxis. Surg Neurol 1985; 23: 559-66.
36. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004; 65: 267-77.
37. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72-6.
38. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000; 27: 661-70.
39. Ma Y, Feigin A, Okulski J, Dhawan V, Chaly T, Eidelberg D. Implementation of atrophy correction in metabolic mapping studies of presymptomatic Huntington's disease. J Cereb Blood Flow Metab 2003; 23: S629.
40. Ma Y, Tang C, Spetsieris P, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007; 27: 597-605.
41. Mattis S. Dementia Rating Scale: profressional manual. Odesa: Psychological Assessment Resources; 1988.
42. Mayberg HS, Starkstein SE, Peyser CE, Brandt J, Dannals RF, Folstein SE. Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease. Neurology 1992; 42: 1791-7.
43. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999; 40: 1264-9.
44. Nelson HE. The National Adult Reading Test (NART): test manual. Windsor, Berks, UK: NFER-Nelson; 1982.
45. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006; 59: 57-63.
46. Paulsen JS, Zimbelman JL, Hinton SC, Langbehn DR, Leveroni CL, Benjamin ML, et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. Am J Neuroradiol 2004; 25: 1715-21.
47. Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003; 126: 1127-35.
48. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006; 66: 1638-43.
49. Reading SA, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, et al. Functional brain changes in presymptomatic Huntington's disease. Ann Neurol 2004; 55: 879-83.
50. Rosas HD, Feigin AS, Hersch SM. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. Neuro Rx 2004; 1: 263-72.
51. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002; 58: 695-701.
52. Ross CA, Aylward EH, Stout JC, Biglan KM, Hayden MR, Shoulson I, et al. Clinical and radiographic features among presymptomatic individuals carrying an expanded CAG repeat in the Huntington's disease gene: analysis of baseline characteristics of the PREDICT-HD Cohort. Neurology 2004; 62: A357.
53. Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005; 20: 674-9.
54. Sandford J, Turner A. Intermediate visual and auditory (IVA). Richmond: Brain Train; 1995.
55. Schmahmann JD, Doyon J, Toga AW, Petrides M, Evans AC. MRI atlas of the human cerebellum. San Diego: Academic Press; 2000.
56. Searle SS, Casella G, McCulloch CE. Variance components. New York: John Wiley & Sons; 1992.
57. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Edu Behav Stat 1998; 25: 323-55.
58. Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press; 2003.
59. Smith A. Symbol Digit Modalities Test (SDMT) manual (revised). Los Angeles: Western Psychological Services; 1982.
60. Smith Y, Raju DV, Pare JF, Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci 2004; 27: 520-7.
61. Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS, Myers RH. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 1991; 41: 1117-23.
62. Spetsieris P, Ma Y, Dhawan V, Moeller JR, Eidelberg D. Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging. Proc SPIE: medical imaging 2006; 6144: 61445M1-12.
63. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999; 45: 25-32.
64. Takikawa S, Dhawan V, Spetsieris P, Robeson W, Chaly T, Dahl R, et al. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. Radiology 1993; 188: 131-6.
65. Tros?t M, Carbon M, Edwards C, Raymond D, Mentis M, Moeller JR, et al. Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol 2002; 52: 853-6.
66. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006; 129: 877-86.
67. van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van der DL, Pruim J, Roos RA, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 2005; 65: 941-3.